Metabolic Complications and Internal Health
At a Glance
LIPE-related FPLD can cause fat to build up in the blood and organs even when someone is not overweight, raising the risk of insulin resistance, diabetes, very high triglycerides, pancreatitis, fatty liver, and heart or kidney problems.
Because your body has a reduced capacity to store subcutaneous fat properly in your legs, the fat must be stored somewhere else. In LIPE-related FPLD (FPLD6), this fat undergoes ectopic accumulation in your blood and internal organs [1]. This process is called ectopic fat deposition—fat stored in places it doesn’t belong—and it is the primary driver of the internal health challenges associated with this condition [2][3].
Importantly, these complications often happen even if you do not appear “overweight” in a traditional sense. Because your legs may be very thin, your body lacks the “safe” storage space for fat that a healthy body has [4].
Insulin Resistance and Diabetes
One of the most common internal effects of FPLD6 is insulin resistance. This happens when your cells stop responding efficiently to insulin, the hormone that moves sugar from your blood into your cells for energy [2].
- The LIPE Connection: When the LIPE gene is altered, normal lipid metabolism is disrupted, which interferes directly with how your body handles insulin [2][5].
- Diabetes Risk: Over time, insulin resistance often leads to type 2 diabetes. In patients with FPLD6, this can appear early in adulthood—sometimes as early as age 20 [6]. Because this diabetes is driven by a lack of fat-storage space, it can sometimes be more difficult to manage than standard type 2 diabetes [7].
Severe Lipid Issues and Pancreatitis Risk
When fat accumulates in the bloodstream, it causes a condition called hypertriglyceridemia—abnormally high levels of triglycerides (a type of fat in the blood) [2].
- Chylomicronemia and Pancreatitis: There is no single safe cutoff: pancreatitis risk begins to rise noticeably when triglycerides are at or above 500 mg/dL (~5.6 mmol/L) and becomes particularly high around or above 1,000 mg/dL (~11.3 mmol/L) [8]. This significantly increases the risk of acute pancreatitis, a dangerous and painful inflammation of the pancreas [8][9].
- Low HDL: Many patients also have very low “good” cholesterol (HDL), which normally helps remove fat from the blood [2][4].
Red Flags for Acute Pancreatitis
You should seek emergency care if you experience these symptoms, especially if your triglycerides are known to be high:
- Severe abdominal pain that starts suddenly and often radiates to your back [9].
- Pain that feels worse after eating or when lying flat.
- Nausea and vomiting accompanying the pain.
- Eruptive xanthomas: Small, yellowish-red bumps on the skin. While these are not themselves an emergency pancreatitis symptom, they indicate severe hypertriglyceridemia requiring prompt evaluation [8].
Liver Health: Steatosis and Fibrosis
Your liver is often the first place “extra” fat is stored. This leads to metabolic-associated steatotic liver disease (MASLD), commonly known as “fatty liver”, and sometimes hepatomegaly (an enlarged liver) [2][6].
- Steatosis: This is the accumulation of fat in liver cells. In FPLD6, this can be severe because the liver is trying to compensate for the fat your legs cannot hold [10][2].
- Fibrosis and Inflammation: Constant fat storage can cause the liver to become inflamed (steatohepatitis). Over time, this inflammation can lead to fibrosis (scarring of the liver tissue) [11][12]. However, this progression is not inevitable, and not every patient develops severe liver disease.
- Monitoring: Because liver enzymes (like ALT or AST) don’t always show the full extent of the damage (they can sometimes be normal despite significant disease), doctors use individualized assessments. Techniques like MRI-PDFF or MR Dixon assess fat content, whereas elastography (like a FibroScan or MR elastography) assesses liver stiffness or scarring [11][13].
Cardiovascular and Renal Surveillance
Your internal-health care plan should also include concrete steps for monitoring other vital systems: clinician-directed atherosclerotic cardiovascular risk screening (including blood pressure) and kidney function testing (such as urine albumin) are critical routine measures for long-term health in FPLD.
Common questions in this guide
Why can LIPE-related FPLD cause metabolic problems even if I am not overweight?
At what triglyceride level does pancreatitis risk become a concern in FPLD6?
How can doctors check for fatty liver or scarring in LIPE-related FPLD?
Which symptoms of pancreatitis mean I should seek emergency care?
What ongoing health checks are important with LIPE-related FPLD?
Questions to Ask Your Doctor
Curated prompts to bring to your next appointment.
- 1.Given my LIPE diagnosis, are my current triglyceride levels high enough to put me at immediate risk for pancreatitis?
- 2.Since I may not appear 'overweight' but have fat in my liver, should we perform a FibroScan or specialized MRI (MR Dixon) to assess liver fat and stiffness?
- 3.How often should we monitor my HbA1c and fasting insulin to catch early signs of insulin resistance or diabetes?
- 4.What is my 'non-HDL' cholesterol level, and how does it affect my long-term heart health?
- 5.How frequently should we monitor my kidney function (such as urine albumin) and overall cardiovascular risk?
Questions For You
Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.
References
References (13)
- 1
The Diagnosis and Management of Lipodystrophy Syndromes: A Multi-Society Practice Guideline.
Brown RJ, Araujo-Vilar D, Cheung PT, et al.
The Journal of clinical endocrinology and metabolism 2016; (101(12)):4500-4511 doi:10.1210/jc.2016-2466.
PMID: 27710244 - 2
LIPE-related lipodystrophic syndrome: clinical features and disease modeling using adipose stem cells.
Sollier C, Capel E, Aguilhon C, et al.
European journal of endocrinology 2021; (184(1)):155-168.
PMID: 33112291 - 3
The dysfunction of hormone-sensitive lipase induces lipid deposition and reprogramming of nutrient metabolism in fish.
Wang JG, Zhao SH, Qian YC, et al.
The British journal of nutrition 2023; (130(4)):588-603 doi:10.1017/S0007114522003622.
PMID: 36408747 - 4
Homozygous LIPE mutation in siblings with multiple symmetric lipomatosis, partial lipodystrophy, and myopathy.
Zolotov S, Xing C, Mahamid R, et al.
American journal of medical genetics. Part A 2017; (173(1)):190-194 doi:10.1002/ajmg.a.37880.
PMID: 27862896 - 5
Rosiglitazone Reverses Inflammation in Epididymal White Adipose Tissue in Hormone-Sensitive Lipase-Knockout Mice.
Kotzbeck P, Taschler U, Haudum C, et al.
Journal of lipid research 2023; (64(1)):100305 doi:10.1016/j.jlr.2022.100305.
PMID: 36273647 - 6
Case report: First Chinese patient with family partial lipodystrophy type 6 due to novel compound heterozygous mutations in the LIPE gene.
Zhou Y, Zhang L, Ding Y, Zhai Y
Frontiers in genetics 2024; (15()):1417613 doi:10.3389/fgene.2024.1417613.
PMID: 39113684 - 7
Lipodystrophy for the Diabetologist-What to Look For.
Patni N, Garg A
Current diabetes reports 2022; (22(9)):461-470 doi:10.1007/s11892-022-01485-w.
PMID: 35821558 - 8
Approach to the Adult Patient with Chylomicronemia.
Hegele RA
The Journal of clinical endocrinology and metabolism 2026; (111(3)):845-859 doi:10.1210/clinem/dgaf701.
PMID: 41472374 - 9
The Chylomicronemia Syndrome Is Most Often Multifactorial: A Narrative Review of Causes and Treatment.
Chait A, Eckel RH
Annals of internal medicine 2019; (170(9)):626-634 doi:10.7326/M19-0203.
PMID: 31035285 - 10
Advanced lipodystrophy reverses fatty liver in mice lacking adipocyte hormone-sensitive lipase.
Pajed L, Taschler U, Tilp A, et al.
Communications biology 2021; (4(1)):323 doi:10.1038/s42003-021-01858-z.
PMID: 33692445 - 11
Waist circumference is independently associated with liver steatosis and fibrosis in LMNA-related and unrelated Familial Partial Lipodystrophy women.
Viola LF, Valerio CM, Araujo-Neto JM, et al.
Diabetology & metabolic syndrome 2023; (15(1)):182 doi:10.1186/s13098-023-01156-0.
PMID: 37679847 - 12
Spectrum of disease associated with partial lipodystrophy: lessons from a trial cohort.
Ajluni N, Meral R, Neidert AH, et al.
Clinical endocrinology 2017; (86(5)):698-707 doi:10.1111/cen.13311.
PMID: 28199729 - 13
Efficacy and Safety of Obeticholic Acid for Treating Hepatic Steatosis in Patients With Familial Partial Lipodystrophy.
Garg A, Vasandani C, Li X, et al.
The Journal of clinical endocrinology and metabolism 2025; (110(11)):e3617-e3625 doi:10.1210/clinem/dgaf173.
PMID: 40080694
This page is for informational purposes only and does not constitute medical advice. It explains metabolic complications and monitoring in LIPE-related FPLD; discuss your triglyceride, glucose, liver, heart, and kidney results with your healthcare team.
Get notified when new evidence is published on LIPE-related familial partial lipodystrophy.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.